Clinical trials: Moderate Psoriasis
Psoriasis
Study Evaluating the Safety and Efficacy of Etanercept 50 mg Once Weekly in Subjects With Psoriasis
The primary objective is to assess the efficacy and safety of etanercept 50 mg administered once weekly in subjects with psoriasis over 12 weeks.
- Trial name
- NCT00333034
- Testing
- Etanercept
- Where
- 23 sites in Austria, Belgium and 8 more
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Moderate to Severe Plaque Psoriasis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase Ⅲ Study to Evaluate the Efficacy and Safety of WD-890 Tablets for the Treatment of Moderate to Severe Plaque Psoriasis
The purpose of the study is to evaluate the experimental medication WD-890 compared to placebo in participants with moderate-to-severe plaque psoriasis.
- Trial name
- NCT07672561
- Testing
- Drug:WD-890
- Where
- China
- Volunteers
- 375 people, healthy volunteers welcome
- Sponsor
- Zhejiang Wenda Pharma Technology LTD.
Psoriasis
The Effect of Riboflavin on Moderate to Severe Plaque Type Psoriasis
The purpose of this study is to determine the anti-inflammatory effect of high-dose riboflavin supplementation on chronic plaque psoriasis. Psoriasis is a common chronic skin disorder that affects over 4 million people.
- Trial name
- NCT02622386
- Testing
- Riboflavin
- Where
- United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- University of Michigan
Plaque Psoriasis
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of ASC50 Tables in Healthy Participants and Participants With Plaque Psoriasis
This is a phase I, randomized, double-blind, placebo-controlled, single and multiple ascending dose study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, food effect of ASC50 tablets in healthy adult…
- Trial name
- NCT07024602
- Where
- United States
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Ascletis Pharma (China) Co., Limited
Psoriasis, Atopic Dermatitis
A Study of EDP1066 in Healthy Participants and Participants With Mild to Moderate Psoriasis and Atopic Dermatitis
Evelo will investigate the safety and tolerability of EDP1066 and its potential to be a medicinal product in healthy volunteers and individuals with mild to moderate psoriasis and atopic dermatitis.
- Trial name
- NCT03542994
- Testing
- EDP1066
- Where
- 7 sites in United Kingdom
- Volunteers
- 114 people, healthy volunteers welcome
- Sponsor
- Evelo Biosciences, Inc.
Plaque-type Psoriasis
Safety Study of Ointment for the Treatment of Plaque-type Psoriasis
The purpose of this study is to determine how much drug is absorbed throughout the body after being applied to the skin.
- Trial name
- AN2728-PSR-104 (NCT01258088)
- Testing
- AN2728 Ointment, AN2728 Vehicle
- Where
- Australia
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Pfizer
Plaque Psoriasis
A Multicenter Study of 074-6751 Lotion in Subjects With Moderate Plaque Psoriasis
The primary objective of this study is to determine the efficacy and safety of 074-6751 Lotion applied twice daily for four weeks (28 days) in clinical subjects with moderate plaque psoriasis.
- Trial name
- NCT03167515
- Testing
- 074-6751 Lotion
- Where
- 5 sites in United States
- Volunteers
- 95 people, healthy volunteers welcome
- Sponsor
- Ferndale Laboratories, Inc.
Psoriasis
Safety and Effectiveness of CNDO 201Trichuris Suis Ova (TSO) for the Treatment of Moderate to Severe Plaque Psoriasis
The purpose of this study is to evaluate the safety and effectiveness of CNDO 201Trichuris suis ova (TSO) for the treatment of moderate to severe plaque psoriasis.
- Trial name
- NCT01836939
- Testing
- TSO 2500, TSO 7500
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Mark Lebwohl
Psoriasis
A Safety/Efficacy Study of a Non-steroid, Topical Cream Treatment of Psoriasis Over 12-weeks
Psoriasis is a chronic inflammatory skin disorder that is characterized by hyperproliferation of the keratinocytes and inflammation of the epidermal and dermal layers of the skin.
- Trial name
- 134993 (NCT01098721)
- Testing
- WBI-1001
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- Welichem Biotech Inc.
Plaque Psoriasis
A Study Comparing Halobetasol Propionate and Tazarotene Topical Lotion 0.01%/0.045% to Duobrii® Lotion (Halobetasol Propionate and Tazarotene Lotion), 0.01%/0.045% (Reference Listed Drug) in the Treatment of Moderate to Severe Plaque Psoriasis.
To evaluate the therapeutic equivalence and safety of halobetasol propionate and tazarotene topical lotion 0.01%/0.045% (Taro Pharmaceuticals U.S.A., Inc.) and Duobrii® Lotion (halobetasol and tazarotene lotion), 0.01%/0.045%…
- Trial name
- NCT05282771
- Testing
- Halobetasol Propionate and Tazarotene Lotion 0.01%/0.045%, Duobrii® Lotion (Halobetasol propionate and tazarotene lotion), 0.01%/0.045%
- Where
- United States
- Volunteers
- 402 people, healthy volunteers welcome
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Psoriasis
An Ascending Multiple Dose Study With VTP-43742 in Healthy Volunteers
This is Part 1 of a two-part, randomized, double-blind, placebo-controlled study in which VTP-43742 was administered to participants; Part 1 in healthy volunteers and Part 2 in psoriatic participants.
- Trial name
- NCT03724292
- Testing
- VTP-43742
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Vitae Pharmaceuticals Inc., an Allergan affiliate
Psoriasis
Open Label Study Etanercept's Maintenance Dose in Obese Patients With Moderate to Severe Plaque Type Psoriasis
This is a single-center, open-label, pilot study. A total of 30 subjects (15 in each study arm) will be enrolled in this 6 month study to evaluate whether the addition of narrow band UVB (NB-UVB) phototherapy can enhance the…
- Trial name
- NCT00800982
- Testing
- Narrow band (310-312 nm) ultraviolet light B phototherapy, etanercept
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Plaque Psoriasis
A Safety and Efficacy Study to Evaluate Efalizumab in Combination With UVB for Moderate to Severe Psoriasis
An open label, single arm study to evaluate the study and efficacy of efalizumab in combination with NB-UVB. Weeks 1-12 efalizumab will be administered once a week in combination with NB-UVB three times per week.
- Trial name
- NCT00302445
- Testing
- Efalizumab, Narrow Band Phototherapy
- Where
- 2 sites in United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Derm Research, PLLC
Atopic Dermatitis, Psoriasis
Study in Healthy Participants and Participants With Moderate Atopic Dermatitis & Optionally, Moderate Psoriasis, and/or Mild Asthma
This Phase 1 study will investigate the safety and tolerability of EDP1867 in healthy volunteers, participants with atopic dermatitis, and, optionally, in participants with psoriasis and/or asthma.
- Conditions
- Atopic Dermatitis, Psoriasis, Asthma
- Trial name
- NCT04927195
- Testing
- EDP1867
- Where
- 7 sites in United Kingdom
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Evelo Biosciences, Inc.
Psoriasis Vulgaris
Safety and Effectiveness of Combined LED Light for the Treatment of Mild to Moderate Plaque Type Psoriasis Vulgaris
The purpose of this study is to investigate whether light therapy can help improve plaque psoriasis. This is a study based on a new medical device. The device produces its light from light emitting diodes.
- Trial name
- NCT03507946
- Testing
- Dermawrap - combined 460nm, 633nm and 830nm LED therapy
- Volunteers
- healthy volunteers welcome
- Sponsor
- Ismart
Mild to Moderate Psoriasis, Healthy Volunteers
A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of UCB0159 in Participants With Mild to Moderate Psoriasis, Single Dose Pharmacokinetics and Safety in Healthy Participants.
The purpose of the study is to evaluate the safety and pharmacokinetics of UCB0159 administered in participants with mild to moderate plaque psoriasis and evaluate single dose pharmacokinetics and safety of UCB0159 in healthy…
- Trial name
- NCT07849894
- Testing
- UCB0159
- Where
- 2 sites in Germany, United Kingdom
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- UCB Biopharma SRL
Psoriasis
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 139 in Healthy Subjects and Subjects With Moderate to Severe Psoriasis
The purpose of this study is to assess the safety and tolerability of AMG 139 following single subcutaneous (SC) or intravenous (IV) dose administration in healthy subjects and subjects with moderate to severe psoriasis (PsO).
- Trial name
- NCT01094093
- Testing
- AMG 139
- Where
- 4 sites in Australia, New Zealand
- Volunteers
- 73 people, healthy volunteers welcome
- Sponsor
- AstraZeneca